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Estrogen modiﬁes human emotion and cognition and impacts symptoms of schizophrenia. We hypothesized
that the variation in the estrogen receptor alpha (ESR1) gene and cortical ESR1 mRNA is associated with
schizophrenia. In a small case–control genetic association analysis of postmortem brain tissue, genotype
CC (rs2234693) and haplotypes containing the C allele of a single-nucleotide polymorphism (SNP) in
intron1 (PvuII) were more frequent in African American schizophrenics (P 5 0.01–0.001). In a follow-up
family-based association analysis, we found overtransmission of PvuII allele C and a PvuII C-containing
haplotype (P 5 0.01–0.03) to African American and Caucasian patients with schizophrenia. Schizophrenics
with the ‘at risk’ PvuII genotype had lower ESR1 mRNA levels in the frontal cortex. Eighteen ESR1 splice var-
iants and decreased frequencies of the wild-type ESR1 mRNA were detected in schizophrenia. In one patient,
a unique ESR1 transcript with a genomic insert encoding a premature stop codon and a truncated ESR1
protein lacking most of the estrogen binding domain was the only transcript detected. Using a luciferase
assay, we found that mRNA encoding a truncated ESR1 signiﬁcantly attenuates gene expression at estro-
gen-response elements demonstrating a dominant negative function. An intron 6 SNP [rs2273207(G)] was
associated with an ESR1 splice variant missing exon seven. The T allele of another intron 6 SNP was part
of a 30 haplotype less common in schizophrenia [rs2273206(T), rs2273207(G), rs2228480(G)]. Thus, the vari-
ation in the ESR1 gene is associated with schizophrenia and the mechanism of this association may involve
alternative gene regulation and transcript processing.
INTRODUCTION
Schizophrenia, like other psychiatric disorders, has a strong
genetic component. One approach to delineating ‘causative’
genes involves analyzing candidates with neurobiological
plausibility in relationship to known characteristics of the
disease, termed ‘functional candidate association studies’ (1).
Many convergent lines of inquiry, from clinical observations,
to measures of brain physiology, and molecular pathology
suggest that estrogen signaling may be altered in the brains of
patients with mental illness. First, the onset of disorders such
as schizophrenia frequently occurs during or just after puberty
(2,3) suggesting that sex steroid-triggered maturational
changes in the brain may unmask vulnerability (4,5). Addition-
ally, gender differences in symptoms (6,7), age of onset and
course of disease over time have been well documented (8,9).
Changes in schizophrenic symptoms are common during
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other periods of ﬂuctuating hormonal levels (9–18).
Estrogen regulates emotional responses (19) and frontal cor-
tical activity during cognitive task performance in humans
(20), both of which are altered in major mental illness.
While the transcriptional effects of estrogen are known to be
mainly mediated by two gene products—estrogen receptor
alpha (ESR1) (21) and estrogen receptor beta (ESR2) (22)—
we have focused our initial efforts on ESR1 as we have
previously found reductions in ESR1 mRNA in cortical and
subcortical brain regions in patients suffering from major
mental illness including a reduction in hippocampal ESR1
mRNA in patients with schizophrenia (23,24). Furthermore,
telencephalic ESR1 mRNA levels signiﬁcantly correlate with
age of onset of schizophrenia and of major depression (23).
ESR1 is located on chromosome 6q25.1, spans over 300 kb,
yields a prototypical mRNA of about 6.5 kb, contains eight
coding exons and undergoes complex transcriptional regu-
lation (25,26). Six alternative promoters regulate ESR1 gene
expression in distinct organs, including brain, with promoters
A, B and C utilized in human hypothalamus, amygdala, hippo-
campus and temporal cortex (27). Alternatively spliced ESR1
transcripts exist and are functionally important as ESR1 is a
modular protein whereby removal of exons translates into
stable proteins with differing ability to bind estrogen, trans-
locate to the nucleus and interact with DNA (28). In frontal
cortex of normal individuals, we have shown that alternative
splicing of the ESR1 primary transcript can result in 12 dis-
tinct splice variants (29). The complement of ESR1 splice
variants in frontal cortex differs between individuals, and we
hypothesized that the variability in ESR1 mRNA isoforms
may relate to psychiatric diagnosis and may be inﬂuenced
by genetic variation in intronic regions proximal to splice
donor and acceptor sites.
In this study, we hypothesized that the brain response to cir-
culating estrogen may be altered in schizophrenia due to
inheritance of particular forms of the estrogen receptor gene
and/or due to the variation in estrogen receptor mRNA. We
tested this possibility by determining if polymorphisms in
the ESR1 gene are associated with the diagnosis of schizo-
phrenia and whether differences in the level or type of cortical
ESR1 transcripts are found in patients with schizophrenia
compared to controls. We employed targeted re-sequencing
of functional regions of the ESR1 gene in patients with schizo-
phrenia to identify rare genetic alterations that may be speciﬁc
to the disorder. We found associations between a functional
SNP in intron one of ESR1 and the diagnosis of schizophrenia
using our case–control brain cohort and conﬁrmed this in a
family-based association cohort. Additionally, we found that
the ‘at risk’ SNP was associated with altered ESR1 mRNA
levels in the frontal cortex of schizophrenics. We determined
that as many as 20% of the patients with schizophrenia did
not have detectable full length, fully functional, ESR1
mRNA in the frontal cortex and one patient produced a
novel form of ESR1 mRNA that introduced a stop codon
before the estrogen binding domain coding region. Further-
more, we found that the sequence variation in intron 6 predicts
the presence of the D7 ESR1 splice variant in brain and is part
of a 3-SNP haplotype associated with schizophrenia. Taken
together, our results demonstrate that the ESR1 gene is a can-
didate to add to the growing list of potential ‘susceptibility’
genes for schizophrenia and that the mechanism of action
includes changes at the mRNA level.
RESULTS
SNP identiﬁcation by targeted re-sequencing
We successfully sequenced 6232 bp out of the 7787 bp
targeted for re-sequencing in all individuals. The 1555 bp
not re-sequenced corresponded to the region upstream of
promoter A, the ﬁrst exon and the 30 ﬂanking region of exon
1 (Fig. 1, Table 1) and were not able to be sequenced
because of high GC content. Within the sequenced regions,
we identiﬁed 44 SNPs. Eleven had very low frequency
(,1%) and showed questionable sequence quality, and thus
are not reported in Table 1. Many SNPs, some of which
were novel, with high sequence quality but with frequencies
1% were found in this sample and were more common in
African American patients (Table 1). Among the novel gene
polymorphisms, we found an insertion/deletion polymorphism
(indel) [-3815_-3816delAA] located at 554 bp upstream from
the alternative transcription start site of exon C large that
was subsequently submitted to NCBI by another group. The
indel was followed by a G to A polymorphism (C1) which
corresponds to rs6903180 in dbSNP. We found that the
presence of the allele with the insert coincided in all cases
with the presence of a G at the C1 SNP locus. Using direct
re-sequencing from our family-based sample, we determined
that the ESR1 promoter Indel was not transmitted in a
Figure 1. A schematic ﬁgure shows the general location of ESR1 common SNPs (arrows) used in association analyses. Gray horizontal bars indicate the regions
of the ESR1 gene that were re-sequenced. The eight coding exons and the insertion are indicated by thin black vertical lines. ESR1 introns are shown as open
horizontal bars (note thy can be grey or white). Numbers at the bottom correspond to exons and letters represent the different alternative start sites of transcription
(indicated on gene with ﬂags). Lines connecting exons C and B to exon 1 represent some of the alternative splicing. Other alternative 50-UTR exons upstream of
exon D are not shown.
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(7.37%). The deletion allele appeared de novo in 33% of the
non-Mendelian transmissions (3/9 transmissions), whereas
the insertion allele appeared de novo in 66% of the non-
Mendelian transmissions (6/9 transmissions). These de novo
polymorphisms were found in both African Americans and
Caucasians.
In African Americans, only PvuII (C11) in intron one and
the promoter Indel were in moderate LD (r
2); whereas most
of the selected markers were not in high LD (Table 2). In
Caucasians, moderate-high LD was found between three
markers in the 50 end of the gene: the Indel (promoter), C4
(promoter) and PvuII (C11, intron 1). Also, in Caucasians,
one SNP in intron 6 (30 end) of the gene (C33) was in
Table 1. Nomenclature for the SNPs used is deﬁned in the far left column. The base pair substitution, the gene region, the rs number and the amino acid changes
are given. The locations of the SNP deﬁned in terms of the location on the chromosome, the intermarker distance and distance from the ﬁrst ATG according to
NM_000125 are computed. The minor allele frequency (MAF) in both racial groups is given for each SNP. The last four columns indicate the diagnosis of the
individuals where rare SNPs (,0.06% frequency) were identiﬁed
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ate LD with a nearby SNP (þ14 bp) in intron 6 (Table 2).
Genetic association analysis
For the African Americans controls derived from the post-
mortem brain cohort, all genotypes were in Hardy–Weinberg
(H–W) equilibrium with the exception of the Indel. In contrast,
not only the Indel but also the C4 and C11 genotypes of African
American schizophrenics showed signiﬁcant deviation from
H–W equilibrium in this cohort. Due to the absence of H–W
in the Indel genotypes in both cases and controls and the
absence of Mendelian transmission in a signiﬁcant percentage
of families, this polymorphism was excluded from the associ-
ation analysis. We detected signiﬁcant genotype frequency
(but not allelic) difference between African American schizo-
phrenics and normal controls at C1, C5 and C11 (PvuII)
(Table 3). However, the comparisons reaching signiﬁcance for
both C1 and C5 included comparisons to the homozygotes
for the rare allele which did not contain any normal controls.
The genotypic association to the common PvuII SNP was
more robust and showed both a signiﬁcant increase in the per-
centage of normals who were heterozygotes and a signiﬁcant
increase in the percentage of schizophrenics who were homozy-
gote for the rare allele (CC genotype) (Table 3). In addition, we
found that several three SNP haplotypes in the 50 end of ESR1,
one of which included the PvuII risk SNP, were signiﬁcantly
associated with schizophrenia using a ﬁxed three SNP sliding
window analysis (Table 4). When using various numbers of
SNPs to form haplotypes with GRASP (2, 3, 4 and 5), the
three SNP haplotypes were found to be the most informative
(data not shown). For the Caucasian patients and controls
derived from the postmortem brain cohort, all SNPs were in
H–W equilibrium, but no signiﬁcant association was found.
Next, we conﬁrmed that the variation in the ESR1 gene was
associated with schizophrenia using an independent cohort, the
African American nuclear families from the NIMHGI sample.
The PvuII-C (C11) allele was signiﬁcantly overtransmitted
to patients with schizophrenia (Table 5, T ¼ 23, NT ¼ 14,
P ¼ 0.03 global P ¼ 0.03). When Caucasians families were
added to the analysis, the overtransmission of PvuII-C allele
was still present (T ¼ 60, NT ¼ 41, P ¼ 0.01, global
P ¼ 0.013). Also, using the NIMHGI sample, the pairwise
transmission disequilibrium test (TDT) analysis in Caucasians
did not show overtransmission of any speciﬁc SNP; however,
we did ﬁnd overtransmission of one 3-SNP haplotype
(C5-T,C10-T,C11-C; T ¼ 24, NT ¼ 14, x
2 ¼ 4.35, global
P ¼ 0.04).
Promoter analysis via bioinformatics
The informatics analysis revealed that the ‘at risk’ haplotype of
the ESR1 promoter was predicted to alter transcription factor
binding (Fig. 2, Table 6). Analysis of the upstream region of
Table 2. The linkage disequilibrium results generated from the African American (upper) and Caucasians (lower) case–control genotypes are plotted for the
INDEL and the ten SNPs used in this study. Note that the correlation coefﬁcient r
2 is plotted above and that D0 is plotted below the diagonal
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as the common allele of C4 introduced or disrupted the
transcription factor binding site (TFBS) for myelin zinc ﬁnger
transcription factor (Myt1), sex-determining re g i o no nt h eY
chromosome, Sry-related HMG box-5 (SOX5) and nerve
growth factor-induced protein C (NGF1C), respectively. In
addition, the PvuII, C11 allele C was predicted to remove the
TFBSs for activating enhancer binding protein 4 (AP-4) in
the sense strand and the zinc ﬁnger protein ZNF238 (RP58)
in the antisense strand. Among the SNPs analyzed for trans-
cription factor binding, C10 and C11 were located in a highly
conserved region across species based on the conservation
track of UCSC genome browser (freeze May 2006). Also,
these two SNPs are located within predicted promoters based
on the El Dorado tool of Genomatix. These results suggest
that C1, C4, C5, C10 and C11 might be functional SNPs inﬂu-
encing ESR1 expression regulation. However, these predictions
need to be conﬁrmed by transcription factor binding exper-
iments as well as by determining the correlation between SNP
genotype and ESR1 mRNA levels in patients.
Relationship of ESR1 genotype and diagnosis to ESR1
mRNA levels
First, we determined that RNA quality, as determined by
Bioaglent RNA integrity number (RIN) value, did not differ
Table 3. Allelic and genotype case–control analysis in African Americans is shown
SNP Alleles Number of cases (frequency) Number of controls (frequency) Allelic
association
Genotype association
a
11 (%) 12 (%) 22 (%) n 11(%) 12 (%) 22 (%) nx
2 P Genotype
comparison
x
2 P
C1
b G/A 35 (0.59) 2 (0.05) 2 (0.05) 39 67 (0.91) 6 (0.08) 0 (0) 73 1.22 0.27 II, III, IV 3.75, 3.69, 3,81 0.05, 0.05, 0.05
C4 C/T 35 (0.88) 3 (0.08) 2 (0.05) 40 70 (0.85) 10 (0.12) 2 (0.02) 82 0 0.96 n.s n.s n.s
C5
b T/C 26 (0.65) 12 (0.30) 2 (0.05) 40 64 (0.76) 20 (0.24) 0 (0) 84 2.86 0.09 II, IV 4.67, 4.27 0.03, 0.04
C10 T/G 17 (0.38) 22 (0.49) 6 (0.13) 45 36 (0.42) 34 (0.40) 16 (0.19) 86 0.01 0.93 n.s n.s n.s
C11
b T/C 16 (0.39) 12 (0.29) 13 (0.32) 41 23 (0.26) 48 (0.55) 16 (0.18) 87 0 0.96 I, III 5.15, 5.97 0.02, 0.02
C16 C/G 38 (0.86) 6 (0.14) 0 (0) 44 68 (0.79) 15 (0.17) 3 (0.03) 86 1.82 0.18 n.s n.s n.s
C25 G/A 35 (0.78) 10 (0.22) 0 (0) 45 66 (0.77) 19 (0.22) 1 (0.01) 86 0.07 0.79 n.s n.s n.s
C32 G/T 16 (0.39) 18 (0.44) 7 (0.17) 41 34 (0.41) 39 (0.47) 10 (0.12) 83 0.29 0.59 n.s n.s n.s
C33 A/G 41 (0.91) 4 (0.09) 0 (0) 45 70 (0.81) 15 (0.17) 1 (0.01) 86 2.37 0.12 n.s n.s n.s
C24 G/A 34 (0.76) 11 (0.24) 0 (0) 45 59 (0.69) 23 (0.27) 3 (0.04) 85 1.06 0.3 n.s n.s n.s
The 10 individual SNPs entered into the analysis are listed in the ﬁrst column and the alleles deﬁned as (1/2) are shown. Both the allelic association
results and genotype associations for the distributions are given. Signiﬁcant genotype associations are bolded. Chi-square and P for the signiﬁcant
genotype comparison. n.s, chi-square and P-value of no signiﬁcant comparisons are not shown.
aGenotype comparisons: I, 11 versus 12; II, 11 versus 22; III, 22 versus 12; IV, (11þ12) versus 22.
bSigniﬁcant deviation from Hardy–Weinberg only in cases.
Table 4. Haplotypes across the ESR1 gene were constructed from adjacent
markers and are depicted vertically with 1 representing the common allele
and 2 representing the rare allele
Marker Haplotypes
a
C1 2
C4 1 1
C 5 2222
C10 2 2 1 1
C11 2 2 1 2
C16 2 2 1
C25 1 1 1
C32 2 2 2
C33 1 2
C24 1
Cases 0.08 0.20 0.10 0.00 0.04 0.02 0.38 0.37 0.01
Controls 0.01 0.05 0.00 0.05 0.06 0.05 0.28 0.22 0.09
P-value 0.003 0.003 0.001 0.06 0.21 0.30 0.18 0.04 0.01
Global P 0.03 0.001 0.02 0.00 0.85 0.40 0.50 0.07 0.03
A three-SNP sliding window haplotype analysis in the African American
case–control sample showed that haplotypes containing rare SNPs in the
50 end of the ESR1 were overrepresented in patients. Haplotypes
containing rare SNP variants in the 30 end of the gene were
overrepresented in controls. Statistically signiﬁcant haplotypes are bolded.
aHaplotypes with the lowest P-valueand with a frequency higher than0.03 in at
least one of the groups.
Table 5. The ETDT analysis in the NIMHGI sample is shown
NIMHGI ETDT
a
SNP name Overtransmitted allele T
b NT
c P
INDEL AA 2 (1) 0 (0) 0.09
C1 G 16 (0.61) 10 (0.38) 0.23
C4 T 17 (0.53) 15 (0.47) 0.72
C5 C 7 (0.54) 6 (0.46) 0.78
C10 T/G 12 (0.5) 12 (0.5) 1.00
C11-PvuII C 39 (0.66) 20 (0.34) 0.01
C16 C 16 (0.64) 9 (0.36) 0.16
C25 G 12 (0.57) 9 (0.43) 0.51
C32 G/T 14 (0.5) 14 (0.5) 1.00
C33 A 16 (0.64) 9 (0.36) 0.16
C24 A 18 (0.56) 14 (0.44) 0.48
The individual ESR1 SNPs tested for transmission are shown in the ﬁrst
column and the overtransmitted allele is shown in the second. When the
alleles were equally transmitted both alleles are shown. Statistically
signiﬁcant over transmission of PvuII C allele is bolded.
aETDT only consider transmissions from informative parents.
bNumber of transmitted alleles (frequency).
cNumber of non-transmitted alleles (frequency).
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compared to controls (RIN ¼ 6.16), ( t ¼ 0.76, df ¼ 65, P ¼
0.45). Since DNA sequence variation in the upstream region
of ESR1 may impact transcriptional rates of the ESR1 gene,
we tested if polymorphisms within the putative promoter,
intron 1 and 50-UTR of ESR1 were associated with ESR1
mRNA levels in the DLPFC of patients with schizophrenia
and/or controls. The PvuII SNP (C11), located in intron 1,
showed no main effect of diagnosis (F ¼ 1.09, P ¼ 0.301,
df ¼ 1, 50) or genotype (F ¼ 0.774, P ¼ 0.467, df ¼ 2, 50),
but did show a signiﬁcant interaction effect (F ¼ 4.54, P ¼
0.015, df ¼ 2, 50). A post hoc LSD test showed that schizo-
phrenic patients with the C/C genotype (homozygous for
‘risk allele’) have signiﬁcantly lower ESR1 mRNA levels
than the patients who are homozygous for T/T (Fig. 3, P ¼
0.025). None of the other 50 SNPs tested (Indel, C1, C4, C5
or C10) showed a signiﬁcant main effect of genotype (all
F   1.93, P  0 .16) or an interaction effect (all F   2.21,
P  0 .14) on ESR1 mRNA level. Our attempts to relate hap-
lotypes to mRNA levels were not successful because dividing
individuals into groups based on haplotypes resulted in small
numbers of subjects in certain haplotype groupings.
Figure 2. Schematic representations of the variation in transcription factor binding sites (TFBS) for the two promoter haplotypes of ESR1 are diagrammed. The
top represents the common haplotype for C4, C5, C10 and C11 (1, 2, 1, 1, 1) that is not associated with the risk for schizophrenia. The bottom schematic shows
the haplotype associated with risk (2, 1, 2, 2, 2). Ovals represent transcription factor binding to either the sense (upper) or antisense (lower) ESR1 DNA strand.
Note the loss of a predicted biding of a transcription factor sites at C4, C5 and C11 and a gain of transcription factor binding site at C10 and Indel-C1 in the risk
haplotype. Black oval, SOX5; grey ovals, MYT1; checkered oval, NGF1C; dotted oval, AP4; hatched oval, RP580 or ZNF238; white oval, myb.
Table 6. Transcription factor binding site analysis of identiﬁed ESR1 promoter SNPs
SNP-allele
a Family/matrix
b TFBS strand Core
similarity
Matrix optimized
threshold
Matrix
similarity
Core sequence
c
indelC1-delC V$MYT1/MYT1.01 2 0.75 0.75 0.76 aaaAACTtcact c
indelC1-delT V$MYT1/MYT1.01 2 0.75 0.75 0.86 aaaAACTtcact t
indelC1-AAG None NA NA NA NA NA
C4-T V$MYT1/MYT1.01 þ 0.75 0.75 0.78 agaCAG T taacct
C4-A V$MYT1/MYT1.01 2 0.75 0.75 0.78 agaAGGTta a ctg
C4-C None NA NA NA NA NA
C5-A V$SORY/SOX5.01 2 1 0.87 0.99 gtca a CAAT ggcc
C5-C None NA NA NA NA NA
C10-T None NA NA NA NA NA
C10-C V$EGRF/NGFIC.01 2 1 0.8 0.80 gagaG C GTgtg t g g
C11-C V$VMYB.05 – 1 0.9 0.95 taaAACGgctggg
C11-A V$RP58/RP580.1 2 0.76 0.84 0.85 aaaaC A GCtg gga
C11-T V$AP4R/AP4.02 þ 1 0.92 0.939 tgtcccAGC Tgtt ttat
The polymorphic change is given in the ﬁrst column, the transcription factor identity is given in the second column. If no transcription factor was
identiﬁed to bind to the interrogated sequence, none was entered in the second column and not available (NA) was entered into the subsequent columns.
The third column shows the transcription factor binding site (TFBS) strand orientation where þ equals the sense strand and where 2 equals the
anti-sense strand. In the last column, the core binding site for the transcription factor within the 30 bp interrogated is bolded and italicized. The position
of the SNP is underlined.
aSNP allele included in the input sequence for MatInspector analysis.
bNone means that the SNP allele evaluated did not modify a TFBS, then the other columns information was not generated (NA).
cCore sequence in bold italic. SNP allele underlined.
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Following the ﬁrst round of ampliﬁcation of cDNA from the
DLPFC, PCR products were often difﬁcult to visualize on
agarose gels (data not shown). After two rounds of PCR, a wild-
type ESR1 mRNA of the expected size (1380 bp) (Fig. 4) was
detected in 24 of 30 patients (80%) with schizophrenia, 13 of
15 patients with major depressive disorder (87%) and 12 of 15
patients with bipolar disorder (80%, Table 7). Other discrete
PCR products were also detected in 47 of 60 patients (Fig. 4A,
note multiple bands). Presumably, PCR products of smaller
sizes represent exon-deleted ESR1 mRNAs; however, identiﬁ-
cation of which exon or exons were deleted based on the size
of the product was not possible at this stage due to the similar
sizes of some of the exons. In the third round of PCRs, where
primers to speciﬁc splice junctions were used, we were able to
detect a transcript population of 121 exon-deleted ESR1
mRNAs representing 18 distinct exon-deleted ESR1 mRNA
transcripts from 60 human patient DLPFC samples using
nested PCR (Fig. 5). We successfully ampliﬁed exon-deleted
ESR1 mRNA variants using all our primer pairs on cDNA
from the DLPFC of patients and their sequence was conﬁrmed.
Detection of an ESR1 mRNA insertion variant
in a schizophrenic patient
After two rounds of PCR ampliﬁcation, one patient with
schizophrenia with no detectable wild-type or exon-deleted
ESR1 mRNAs was found to express an ESR1 mRNA larger
than wild-type (1493 bp, Fig. 4A) with unpredicted sequence
between exons 4 and 5. By using PCR primers targeted to
exons 4 and 5, we detected 113 bp of sequence cleanly
inserted between the last base of exon 4 and the ﬁrst base of
exon 5 (Fig. 4B). This sequence mapped to the ESR1 gene
in the intron between exons 4 and 5 (Genbank accession no.
AY425004.1 bases 177879–177991 in 6q25.1). The predicted
protein coded by this variant mRNA would be 383 amino
acids long with a stop codon at the end of exon 4 that
would result in a truncated protein and absence of the estrogen
binding domain.
Altered frequency of ESR1 transcripts in patients
with major mental illness
Using the same methodology previously employed on the
same brain region of 29 normal controls (29), we observed
wild-type and 9 exon-deleted ESR1 mRNA variants in
common with patients diagnosed with schizophrenia, bipolar
disorder and major depressive disorder. Three ESR1 exon-
deleted mRNA variants detected previously (D2,4,7, D6, and
D7,2,3,4) were not observed in any of the 60 patients, although
they had been found at only low frequency in normal controls
(29). Six ESR1 exon-deleted mRNA variants not observed in
normal controls (D3, D3,7, D5,2,3, D7,5, D7,2,3,4,5, and
D7,2 3,4,5,6 ) (with only partial deletions of exons 2 and 6)
Figure 3. Scatter plot showing the average quantity of ESR1 mRNA levels normalized to the geometric mean of four housekeeper (HSKPs) mRNAs on the Y-axis as
determined by real time qPCR. The values of ESR for patients with schizophrenia are plotted according to the PvuII (C11) genotype with C being the risk allele.
Those patients homozygous for the risk allele (CC), have signiﬁcantly lower expression compared to the other genotype groups (T/C and T/T).  P . 0.05.
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quency (Fig. 5, Table 7). We tested if the frequency of the two
most common ESR1 transcripts (wild-type and D7 ESR1) dif-
fered in controls and patients with major mental illness, and
we found that the frequency of wild-type ESR1 mRNA
expression was lower in patients with schizophrenia (80%)
when compared with normal controls (97%) (x
2 ¼ 3.86,
df ¼ 1, P , 0.05) (Fig. 5, Table 7). We noted that there
were also 20% of the patients with bipolar illness that
lacked the wild-type ESR1 transcript; this did not, however,
reach statistical signiﬁcance likely due to the reduced power
with the smaller number of subjects in the bipolar group. In
the patients with major depression, we detected a higher
frequency of the D7 ESR1 mRNA (80%) when compared
with normal controls (48%) (x
2 ¼ 4.12, df ¼ 1, P , 0.05)
(Table 7). Isoform variants were not found to vary signiﬁ-
cantly according to race or gender (29).
D7 ESR1 attenuates the wild-type ESR1 response
to estrogen
Considering that patients with schizophrenia were more likely to
express ESR1 splice variants, we determined if they could have
a functional impact on wild-type ESR1 signaling. Since the D7
ESR1 transcript was the most abundant ESR1 splice variant in
human brain and was associated with mental illness, we tested
whether expression of the D7 ESR1 transcript would impact
ESR1 mediated gene transcription. Using an estrogen-response
element (ERE)-driven luciferase reporter construct containing
three tandem repeats of a palindromic ERE, we ﬁrst determined
the ability of the wild-type ESR1 and D7 ESR1 to activate gene
expression at different concentrations of 17b-estradiol
(Fig. 6A). We showed that overexpression of wild-type ESR1
potently (about 3.6 times control vector) stimulated ESR1
mediated transcription in a concentration-dependent fashion
(Fig. 6A), while overexpression of D7 ESR1 failed to elicit a
transcriptional response at any dose. Next, we determined
if the D7 ESR1 variant elicited a dominant negative effect on
the wild-type ESR1 transcriptional response in the presence
and absence of exogenous estrogen. We found a very signiﬁcant
difference in transcriptional activity in our four treatment
conditions (F ¼ 1136.9, df ¼ 3,20, P , 0.001) (Fig. 6B).
Importantly, when wild-type ESR1 was co-expressed with the
D7 ESR1 mutant, the increase in wild-type ESR1-mediated
transcription in the presence of 17b-estradiol was attenuated
by over 50% (P , 0.0001). Additionally, a more modest but
also statistically signiﬁcant repression was found without the
addition of exogenous estrogen, perhaps due to local estrogen
synthesis by CHO cells in culture.
ESR1 polymorphisms and ESR1 exon-deleted mRNA
variant detection
Since intronic ESR1 DNA sequence variation may impact on
splicing of ESR1 transcripts, we asked if three distinct SNPs,
C25, C32 or C33, all in introns and preceding one of the two
Figure 4. (A) The PCR products produced after nested PCR for ESR1 from cDNA derived from the DLPFC of patients with schizophrenia. Note that the samples
are migrating on a slight downward diagonal. Lane 1 contains the 100 bp DNA ladder (L). The bright band in the ﬁrst three sample lanes (lanes 2–4) and the last
2 lanes (15 and 16) corresponds to the expected 1380 bp amplicon (horizontal arrow). This 1.4 band would be predicted if all 8 coding exons were present in
the ESR1 transcript (wild-type). Many bands with smaller than the predicted sizes are found in the range of 1 to 1.3 kb and can occur in different individuals (for
example, compare lanes 4 to lane 5) or within the same individual (lanes 7, 8, 11, 13 and 14). The exact identities of these bands could not be deﬁnitively
identiﬁed at this stage (see Materials and Methods). Note that in lanes 5, 6, 7 and 10 no wild-type bands are detected. In the 12th lane, a larger than predicted
amplicon was observed (vertical arrow, 1493 bp). In panel B, the 1493 bp ESR1 transcript was conﬁrmed to be about 100 bp longer by a separate PCR directly
targeting ESR1 exons 4 and 5 in normal individuals (N) and in the patient with schizophrenia with this genomic insertion (S).
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tion of the D5o rD7 ESR1 splice variants. Indeed, individuals
whose ESR1 transcript pool contained speciﬁc exon 7-deleted
mRNAs were more likely to have the common G allele at the
intron 6 (C32 SNP) when compared to a T allele (x
2 ¼ 4.48,
df ¼ 1, P ¼ 0.034). The two other SNPs tested did not associ-
ate with the presence of either D5o rD7 containing transcripts.
The C32 SNP was part of an associated haplotype (protective)
detected at the 30 end of the gene (Table 4).
DISCUSSION
ESR1 gene is associated with schizophrenia
In this study, we detected association of the estrogen receptor
alpha gene with schizophrenia in two samples. Genotype (CC)
of ESR1 SNP in intron 1, the PvuII (C11), was signiﬁcantly
associated with the diagnosis of schizophrenia in our African
American case–control sample of postmortem brain tissue.
Furthermore, SNP haplotypes located at the 50 end of the
gene and extending from the promoter into intron 1 were
associated with the diagnosis of schizophrenia in this
sample. The 30 region of the ESR1 gene also showed some
association when ESR1 haplotypes were analyzed. In an
independent group of patients, we found further support for
genetic association between the variation in the ESR1 gene
and schizophrenia. The C allele of C11 found to be
over-represented in patients with schizophrenia in the brain-
derived case–control sample, was preferentially overtrans-
mitted to offspring with schizophrenia using TDT analysis in
the NIMHGI sample. Furthermore, the CC genotype at PuvII
(C11) predicted lower ESR1 mRNA levels in patient pre-
frontal cortex. We found that the PvuII (intron 1) SNP was
in moderate LD with a common insertion–deletion poly-
morphism (Indel) that we identiﬁed in the 50 domain of the
ESR1 gene (this Indel was deposited to NCBI by a different
group during the course of our study). Additionally, we identi-
ﬁed other rare ESR1 gene variants especially in patients. We
observed signiﬁcant deviation from H–W equilibrium in the
genotype distribution of Indel, C1, C4 and C11 (PvuII) in
patients with schizophrenia again suggesting an association
between these polymorphisms and schizophrenia (30). It is
unlikely that the deviations from H–W are due to genotype
errors because many of these SNPs were conﬁrmed by direct
sequencing and the assigned genotypes were each veriﬁed
manually. Also, the H–W deviation was not due to an
excess of heterozygous individuals which is characteristic of
genotyping errors. Taken together, our results suggest that
DNA variants in the upstream region of the ESR1 gene may
impart risk to developing schizophrenia and that the mechan-
ism of this risk may involve altered transcriptional control of
cortical ESR1 mRNA.
Genomic and mRNA changes in ESR1 implicate
the promoter
Our computational bioinformatics analysis revealed that the
variation at the 50 end of the gene predicted altered transcrip-
tion factor binding creating or deleting putative binding sites
for ﬁve distinct transcription factors. However, two of these
transcripts, Myt1 and SOX5, are expressed at fairly low
levels in the adult (31,32), but are more abundantly expressed
in the developing brain and have been linked to oligodendro-
cyte (Myt1) and cortical neuron development (SOX5) (33,34).
AP4 and ZNF238 (also known as RP58) are expressed in
cortical neurons (35,36). The most abundant of these potential
ESR1 regulators is ZNF238 which is robustly expressed in the
human prefrontal cortex and decreases signiﬁcantly during
postnatal life (data not shown). The NGF1C transcription
factor (also known as EGR4) is expressed at a low to moderate
level in the adult cortex and has been shown to be genetically
linked to schizophrenia (37) and up-regulated by the antipsy-
chotic, aripiprazole (38).
Changes in transcription factor binding could lead to reduced
levels of ESR1 mRNA similar to what we have previously
found in the brains of patients suffering from major mental
illness (23,24). However, in our previous studies, genotype
was not taken into consideration in the analysis. Direct experi-
mental evidence shows the 1.3 kb intronic region of the ESR1
promoter containing the same polymorphic site which we
have associated with schizophrenia [PvuII (C11)], is functional
and changes transcriptional rate (39). In our study, we report
evidence that patients homozygous for the C11 risk SNP
(CC) have signiﬁcantly reduced ESR1 mRNA in human
frontal cortex. Indeed, we found that the presence of a C in
the canonical CAGCTG site (with C11 underlined) of the
gene was predicted to lead to a loss of AP-4 (transcriptional
Table 7. All of the distinct ESR1 transcripts detected in the human prefrontal
cortex are listed in the far left column
mRNA variant Normal
n ¼ 29
Schizophrenia
n ¼ 30
Depression
n ¼ 15
Bipolar
n ¼ 15
WT (sign 1) 96.6 80.0 86.7 80.0
D 2 27.6 10.0 46.7 26.7
D 2,5 17.2 6.7 26.7 20.0
D 2,7 24.1 13.3 33.3 20.0
D 2,4,7 6.9 0.0 0.0 0.0
D 2,5,7 10.3 3.3 6.7 0.0
D 3 0.0 3.3 6.7 6.7
D 3,7 0.0 6.7 13.3 13.3
D 4 20.7 16.7 6.7 6.7
D 4,7 17.2 10.0 13.3 13.3
D 5 20.7 26.7 46.7 46.7
D 5,2,3 0.0 0.0 6.7 0.0
D 6 3.4 0.0 0.0 0.0
D 7 (sign 2) 48.3 40.0 80.0 53.3
D 7,5 0.0 6.7 6.7 0.0
D 7,3
a,4,5
a 6.9 3.3 0.0 0.0
D 7,2,3,4 3.4 0.0 0.0 0.0
D 7,2,3,4,5 0.0 0.0 6.7 0.0
D 7,2
a,3,4,5,6
a 0.0 0.0 6.7 0.0
INSERTION i4 0.0 3.3 0.0 0.0
WT, wild-type and D, delta followed by the missing exon number(s) are
shown. The percentage of individuals in each diagnostic group where a
particular ESR1 transcript was detected is given in the table. Note that
since the same number of patients with bipolar and depression was
evaluated, these percentages can sometimes be identical. Signiﬁcant
differences in frequency between the diagnostic groups compared to the
normal control group are indicated with (sign). Signiﬁcant difference
(P , 0.05) between schizophrenic and normal controls (sign 1).
Signiﬁcant difference (P , 0.05) between depressives and normal
controls (sign 2).
aOnly partial exon is present in transcript.
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(transcriptional repressor) binding on the antisense strand,
both of which would be expected to lower steady-state ESR1
mRNA (40,41). The other SNPs that are part of the ‘at risk
haplotype’ containing C5 and C10 were also predicted to
modify the binding of transcription factors SOX5 and NGFC1
to the upstream region of the alternatively spliced 50 exon C.
ESR1 polymorphisms–disease comparison
Other studies suggest that the sequence variation in intron 1 of
the human ESR1 may be associated with disease susceptibility
as common SNPs in this genomic region, including PvuII, are
linked to a variety of common human diseases, including
breast cancer (42), osteoporosis (43,44), stroke (45), adiposity
(46), atherosclerosis (47) and Alzheimer’s disease (48).
Furthermore, polymorphisms in intron 1 of ESR1 have been
associated with risk of developing cognitive impairment in
older women suggesting that these alleles may have functional
consequences in the human brain (49). Despite widespread
associations of ESR1 to many diseases including those impact-
ing the brain, our study is the ﬁrst to link common sequence
variation in the estrogen receptor alpha gene to human brain
ESR1 mRNA levels and to the risk of developing schizo-
phrenia. However, it should be noted that there has been con-
siderable evidence for linkage between loci on the long arm of
chromosome 6, where ESR1 is located, and schizophrenia
including a maximum multipoint LOD score of 7.7 on 6q25
in one of the largest pedigrees studied to date (50,51).
Further support implicating the ESR1 locus as being involved
in mental illness comes from one study that scanned about
5 kb of the ESR1 locus in 240 individuals with psychiatric
disorders and identiﬁed four rare missense mutations in one
bipolar, one alcoholic, one schizophrenic and one puerperal
psychosis patient (52). In addition, the two common
polymorphisms (Xba1 and PvuII) found in intron 1 of the
Figure 5. Schematic view of the ESR1 transcripts detected from cDNA from the DLPFC of adult humans. Nineteen different exon-deleted ESR1 mRNAs are
depicted with the boxes representing the 8 known coding exons according to Genbank entry NM_000125.  the partial exon deletion, N the variant only detected
in normal controls, P the variant only detected in psychiatric patients. WT ¼ wild-type ESR1.
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depression in females, whereas no association with diagnosis
of bipolar disorder or schizophrenia has been detected to
date (53–56). The reasons for the discrepancy among our
study and previous studies are not known but may relate to
ethnic differences since our most positive evidence for associ-
ation to ESR1 was found in African American individuals.
ESR1 splice variants are common in schizophrenia
and in depressive patients
We found that patients with schizophrenia were signiﬁcantly
less likely to express the fully functional wild-type ESR1 tran-
script when compared with normal controls, with up to one-ﬁfth
of the patients with schizophrenia lacking any detectable wild-
type ESR1 mRNA in their frontal cortex. The decreased fre-
quency of the wild-type ESR1 in patients with schizophrenia
was detected by one round of nested PCR; however, the
various ESR1 splice variants were identiﬁed by two rounds of
nested PCR and varied considerably from patient to patient.
Since more than one nested procedure has substantial risk
to amplify very minor or even ‘junk’ isoforms, the biological
signiﬁcance of these rare transcripts is not known. However,
we did show that the expression of the commonly occurring
D7 ESR1 splice variant was unable to elicit a transcriptional
response at EREs, in line with previous studies which also
reported a similar attenuation in ESR1 activity via various
splice variants (28,57). Thus, we speculate that patients with
schizophrenia may have a blunted molecular response to estro-
gen which may render the frontal cortex of many patients with
schizophrenia unable to respond normally to brain estrogen.
This could be biologically signiﬁcant because changes in
estrogen levels cause molecular and spine density changes in
the prefrontal cortex (58–61). Additionally, treatment with
estrogen can be an effective adjunctive therapy in some
women with schizophrenia (62,63). One patient with schizo-
phrenia synthesized only ‘mutant’ ESR1 transcript which con-
tained an insertion of genomic DNA that leads to a truncated
ESR1 protein missing the hormone binding domain rendering
this individual’s frontal cortex estrogen insensitive. Considering
this, we would expect that some patients with schizophrenia
may not be able to respond to ‘estrogen therapy’.
Other patients, with major unipolar depression, were more
likely to express the D7 ESR1 mRNA, compared to unaffected
controls suggesting that unipolar depressed individuals may be
more likely to express the dominant negative form of the
ESR1 receptor which could alter the brain estrogen response.
Indeed, we observed that the D7 ESR1 dampened the tran-
scriptional activation mediated by wild-type ESR1 in response
to estrogen in cultured cells. Additionally, circulating levels of
estrogen are found to correlate with symptoms of major mental
illness, especially with depression. Thus, alterations in sex
hormone signaling in depressed patients could involve either
altered circulating levels of sex steroids or altered endogenous
brain response capabilities or both (29).
Rare genomic variations in ESR1 are common
in patients with schizophrenia
After sequencing approximately 7 kb of genomic DNA in 162
individuals, we discovered novel SNPs in the ESR1 gene,
most of which were rare and were typically detected in only
one individual in our study. Patients with schizophrenia
were more likely (13%) to have novel SNPs when compared
with the non-schizophrenic individuals (6%). Interestingly,
we identiﬁed six novel SNPs in the 50-UTR of the transcript
originating from exon C from six different patients with
schizophrenia. The fact that we ﬁnd many rare variants in
ESR1 in schizophrenia is intriguing as there is interest in the
possibility that multiple rare variants could underlie common
diseases such as schizophrenia (50). Changes in the 50-UTR
of mRNAs can inﬂuence mRNA targeting and translation,
change secondary mRNA structure and alter mRNA stability.
For ESR1 mRNA, a recent study has found that transcripts
with distinct 50-UTRs have different translational efﬁciencies
(64). Thus, it may be that in addition to (i) having altered
frequency of genetic variation in a promoter of ESR1 that is
link to reduced ESR1 mRNA levels, (ii) being less likely to
splice together a fully functional wild-type ESR1 transcript,
or (iii) synthesizing only a ‘mutant’ ESR1 transcript (our
study and previous); patients with schizophrenia may be
more likely to have rare genetic variation in the 50-UTR
ESR1 transcript. Each of these changes could independently
or synergistically act to alter ESR1 protein production and
ultimately, blunt estrogen function in brain. In this study, we
have discovered several ways for ESR1 to differ in patients
Figure 6. Cells were transiently transfected for 24 h with 3x ERE-luc and
phRL-TK Renilla internal control plasmid together with either pDsRed-
express-C1 (empty vector control), pDsRed-wt-ESR1 or pDsRed-D7-ESR1.
Following transfection, cells were incubated for 24 h in the absence or pre-
sence of the indicated concentrations of 17b-estradiol (A)o r5 0 p Mo f
17b-estradiol (B). Values are mean þSEM averaged from n ¼ 6 replicate cul-
tures and presented as luciferase activity relative to the empty vector construct
of the vehicle-treated control condition (   P , 0.001 by LSD or Tukeys).
Human Molecular Genetics, 2008, Vol. 17, No. 15 2303with schizophrenia compared to normals. We speculate that
these genomic and transcriptomic differences in ESR1 could
possibly lead to the same cellular fate, unresponsiveness to sex-
steroid driven maturational brain changes during adolescence.
Summary
Since ESR1 is a complex genomic unit with transcription
controlled by at least six promoters (65) and with at least 15
alternative splice variants of the coding domain, there is
much opportunity for individual variation in how the ESR1
gene is expressed. Our data would suggest that the type and
pattern of ESR1 transcripts may be altered in people suffering
from schizophrenia. Our analysis suggests that the expression
of ESR1 splice variants may be biased by genetic variation in
the ESR1 gene. Furthermore, we present evidence that DNA
variation in the 50 region of the ESR1 gene may impact the
susceptibility to developing schizophrenia and ESR1 mRNA
levels in cortex. Taken together, our study suggests that
ESR1 may be a ‘candidate gene’ for schizophrenia worthy
of further investigation.
MATERIALS AND METHODS
In order to link ESR1 genomic changes with changes in ESR1
mRNA, the primary analysis of this paper was accomplished
with postmortem brains of patients with schizophrenia com-
pared to controls (Table 8, Supplementary Material, Cohort 1)
and conﬁrmatory genetic analysis was done on blood DNA
from a sample of live patients and controls. Different subsets
of individuals were used for the DNA re-sequencing (all
cases Table 8) and case–control genetic association analysis
from brain DNA (all Caucasians and African American
normals and schizophrenics from Table 8), for the family-based
genetic association from blood DNA (NIMHGI, Cohort 2), for
the measurement of ESR1 mRNA via qPCR from brain RNA
(Supplementary Material, Cohort 3), and for the ESR1 splice
variant detection from brain RNA (Supplementary Material,
Cohort 4). The decision of which samples to include in each
of the various assays was based on availability of DNA, RNA
and or cDNA at the time the experiment was initiated. We
included patients with bipolar and depression as diagnostic con-
trasts to patients with schizophrenia for the ESR1 splice variant
analysis based on a prior written agreement with the Stanley
Foundation to include all of the diagnostic groups when using
brains from their collection.
Postmortem diagnosis and exclusion criteria
for samples from brain
Brains were collected in the Section on Neuropathology of the
Clinical Brain Disorders Branch (CBDB) of the NIMH and the
Stanley Foundation through the medical examiner ofﬁces fol-
lowing autopsy and through donations via funeral homes with
consent from the next of kin. Psychiatric diagnosis was deter-
mined by telephone interviews with next-of-kin (including the
Structured Clinical Interview for DSM-IV and the NIMH
autopsy interview), and by review of all available clinical
records and the Diagnostic Evaluation After Death (DEAD)
(66,67). Cases that met DSM-IV criteria for schizophrenia,
major depression and bipolar I disorder were used in our
study. Disagreements between the two independent reviews
were resolved by requesting an additional review by a third
psychiatrist. Clinical information, neuroleptic dose calcu-
lations and brain tissue processing of the Stanley and NIMH
cohorts have been previously described (68,69). Detailed
inclusion and exclusion criteria for the schizophrenia cases
used has been previously published (68,70).
Patient cohorts
Postmortem brains (from CBDB and Stanley Foundation).
Two hundred and sixty-eight human brains of psychiatric
patients and normal controls were obtained from the Clinical
Brain Disorders Branch of the National Institute of Mental
Health under an approved NIMH protocol (90M-0142) for
human tissue and from the Stanley Medical Research Institute
(Bethesda, MD, USA). This cohort included 143 non-psychiatric
controls and 95 schizophrenics. Genomic DNA from 132 indi-
viduals (which included all but one patient with schizophrenia)
from this cohort was sent to Polymorphic DNA Technologies,
Inc. (Alameda, CA, USA) for targeted re-sequencing and SNP
discovery (94 schizophrenics and 38 normals).
Clinical Sample from the National Institutes of Mental Health
Genetic Initiative (NIMHGI). We used a subset of the
NIMHGI samples consisting of 122 nuclear families and
including one or two affected offspring (either schizophrenic
and/or schizoaffective diagnosis) and at least one parent (51
African Americans families, 71 Caucasian families). This
subset was constructed from the larger affected sib pair
dataset to maximize the number of trios available for
family-based association analyses. The diagnosis evaluation,
collection and DNA isolation performed in the NIMHGI has
been previously described (71).
Table 8. Demographics for all postmortem brains used in this study are given
Diagnosis n ¼ 268 Mean PMI Mean age Gender (n) Mean pH Race
Schizophrenia 95 36.88+18.20 49.75+16.95 M ¼ 62, F ¼ 33 6.36+ 0.29 AA ¼ 46, CA ¼ 43, AS ¼ 3, H ¼ 3
Bipolar 15 32.53+16.12 42.33+11.7 M ¼ 9, F ¼ 6 6.18+0.23 AA ¼ 1, CA ¼ 14
Depressive 15 27.46+10.72 46.53+9.31 M ¼ 9, F ¼ 6 5.76+0.22 CA ¼ 15
Control 143 29.14+13.74 42.41+15.19 M ¼ 96, F ¼ 47 6.48+ 0.32 AA ¼ 84, CA ¼ 51, AS ¼ 3, H ¼ 5
The number of subjects in each group (n) and theaverage postmortem interval (PMI), age at deathand tissue pH (þ/2 the standard error of themean) are
tabularized. M, males and F, females. AA, African Americans; C, Caucasians; AS, Asians; H, Hispanics. PMI, postmortem interval.
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Genomic DNA was extracted from pulverized frozen brain
(cerebellum or frontal pole) according to the protocol provided
by the manufacturer of the extraction buffers (PureGene).
Total RNA was extract from all cases from the dorsolateral
prefrontal cortex (DLPFC) tissue dissected from the middle
frontal gyrus. Frozen brain tissue was pulverized on dry ice
and weighed while frozen prior to RNA extraction with the
TRIZOL Reagent method (Life Technologies Inc., Grand
Island, NY, USA) as previously described (72).
SNP detection by targeted re-sequencing and genotyping
We selected the following genomic regions to re-sequence in a
search for novel DNA sequence variants related to transcriptional
control or alternatively processed ESR1 transcripts: (i) 3.8 kb
upstream of the ESR1 translation start site comprising the A, B
and C promoters as deﬁned by Kos et al. (25); (ii) the eight
coding exons; (iii) a cassette exon in intron 4 (identiﬁed herein
via RT–PCR); and (iv) 200 bp surrounding each exon of the
ESR1 gene for a total of 7787 bp of brain DNA. Polymorphic
DNA Technologies, Inc. (Alameda, CA, USA) performed the
sequencing and SNP discovery by nucleotide comparison of
single and bidirectional DNA sequences traces with the Paracel’s
AutomatedGENotypingTool(AGENT)program.Weveriﬁedthe
reported SNPs with Mutation surveyor program version 2.51 by
visual inspection, sequence quality (.10) and mutation score
(.20) which correspond to a conﬁdence of 99% for correct
call. To determine if a veriﬁed SNP was novel or known, the
sequence around the SNP was submitted to the BLAT tool of
University of California Santa Cruz (UCSC) genome browser
on human assembly May 2006 and conﬁrmed at dbSNP build
126. SNPs with a minor allele frequency (MAF) higher than
5% in at least one of the populations (Caucasians or African
Americans) were selected to be genotyped by TaqManw assays
in 99 additional normal control brains (70% African Americans,
30% Caucasians) and in 122 NIMHGI nuclear families. Applied
Biosystems’ (ABI) TaqManw primers and probes were
constructed using either the ABI ‘assays by design’ or ‘assays
on demand’ software and the assays were performed under
standard conditions: 508Cf o r2 m i n ,9 5 8C for 10 min and
then 40 cycles of 958C for 30 s, 608C for 1 min. The indel and
C1 genotypes were obtained by re-sequencing the promoter
region in these additional 99 controls (Polymorphic, Inc.).
Genotypes generated with TaqManw assays were manually
assigned using SDS 2.2.2 software with 10% sample redun-
dancy to estimate genotyping accuracy (over 99%) and
assays were repeated until over 98% of the genotypes were
determined. Direct comparisons between genotypes obtained
by direct sequencing and TaqManw in a subset of 45
people, showed that 9/10 SNPs had over 98% consistency.
However, due to high level of inconsistencies in genotypes
of one SNP (rs9340799, XbaI), the data for this SNP were
deemed unreliable and were dropped from all analyses.
Bioinformatics analysis–promoter analysis
A 30 nucleotide sequence surrounding each of the SNPs in the
associated promoter haplotypes, C4,C5,C10 and the intron 1
SNP C11 were tested for introducing or disrupting a TFBS
searching in the matrix family vertebrate library version 5.0
released on February 2005. We used the MatInspector tool of
the Genomatix suite which uses position-speciﬁc weight
matrices (PWMs) to calculate matrix similarity scores for the
two versions of the sequence differing only in the SNP nucleo-
tide. A good matrix similarity score is higher than 0.8 and a
score of 1.0 is only reached when highest conserved bases of
a matrix match exactly the target sequence. To reduce the
number of false positives, the optimized matrix similarity
score is also calculated. In a reliable prediction, the matrix simi-
larity score is higher than the optimized matrix similarity score
(73). The El Dorado tool of Genomatix was used to determine
if any of the SNPs of interest were located within known or
predicted promoters of the ESR1 gene.
qPCR from brain RNA
One hundred and forty-three brains of schizophrenic patients
(n ¼ 53) and normal controls (n ¼ 90) were available for
qPCR (subset of Table 8, see Supplementary Material infor-
mation). Extensive clinical and molecular characterization of
this cohort has been recently described (68). Some samples
were excluded (n ¼ 21) after a rigorous evaluation of RNA
quality and factors inﬂuencing the expression of housekeeping
genes (68). From this reﬁned cohort, we chose a subset of 34
controls (n ¼ 17 African American) and 34 schizophrenics
(n ¼ 16 African American) matched for age, pH and PMI
(see Supplementary Material tables), in order to examine
any diagnostic difference in patients versus controls taking
ESR1 genotype into consideration by two-way ANCOVA.
We veriﬁed that the various genotype groupings formed did
not signiﬁcantly differ in subject age, brain pH, postmortem
interval (PMI) or RNA integrating (RIN).
ESR1 mRNA expression levels were measured from RNA
extracted from the dorsolateral prefrontal cortex. We syn-
thesized ﬁrst-strand cDNA using random primers and following
the standard protocol outlined in the Invitrogen Superscript
First-Strand Synthesis System (Invitrogen life technologies,
Carlsbad, CA, USA). The qPCR assays were performed with
TaqManw technology on an ABI 7900 HT SDS machine
(Applied Biosystems, Foster City, CA, USA). A probe with
t h es e q u e n c e5 0-ATGATGAAAGGTGGGATACGAAAAG-30
was designed to anneal to the junction of ESR1 exons 3 and
4 which was chosen to include the greatest number of exon
deleted mRNA variants [D3a n dD4 are among the least
common deletions (29)]. Each qPCR reaction contained 3 ml
cDNA template (corresponding to 90 ng cDNA), 5 mlM a s t e r
Mix (Eurogentec, California), 0.5 ml 20X assay-on demand
mix containing forward and reverse primers and FAMTM dye-
labeled TaqManw MGB probe (Hs00174860_m1) and 1.5 ml
H2O. Both standards and samples were assayed in triplicate
and gene expression levels were calculated as an average of
the three. Samples were heated for 2 min at 508C and 10 min
at 958C and then subjected to 40 cycles of denaturation at
958C for 15 s and annealing and elongation at 608Cf o r1m i n .
PCR data were acquired from the Sequence Detector Software
(SDS version 2.2, Applied Biosystems) and quantiﬁed by the
relative standard curve method using serial dilutions of pooled
cDNA. SDS software plotted real-time ﬂuorescence intensity
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amplicon proﬁles. The software plotted a standard curve of
the CT (cycle threshold) versus the RNA quantity. Triplicate
measures were made and values with over a 3% standard
deviation (CT) were omitted in calculating the averages per
subject. ESR1 mRNA levels were normalized by dividing
the ESR1 quantities by the geometric mean of the quantity
of four housekeeper genes: SDHA (Hs01549169_m1), GUSB
(Hs99999908_m1), PGDB (Hs00609297_m1) and cyclophilin
A (Hs99999904_m1). No-template controls and no RT controls
were included in the qPCR reaction plate and showed no
detectable ﬂuorescence.
ESR1 mRNA variant detection
Due to the multiple rounds of PCR, and the numerous gels and
successive sequencing needed to determine the entire pool of
ESR1 variants in each subject, we preformed a complete tran-
script ESR1 characterization on a restricted set of cases that
was available when the experiments were initiated. Patients
with bipolar disorder and depression were included (n ¼ 15
and n ¼ 15) in this assay. For diagnostic comparisons, patients
with schizophrenia were matched to normal controls based on
gender, race, brain pH and PMI. Demographic variables for
the individuals used in the ESR1 variant analysis (n ¼ 89) are
described in supplementary information (Supplementary
Material, Table S4). Three rounds (two nested) of PCR were
used to amplify exon-deleted ESR1 mRNA variants from
cDNA synthesized from frontal cortex as described above.
Primers, cycle conditions, and expected fragment sizes for all
three rounds of PCR have been previously described (29). In
one schizophrenic case, after the ﬁrst two rounds of PCR, a
product 100 bp greater than expected size was ampliﬁed (see
results, Fig. 5). Upon bidirectional sequencing, unpredicted
sequence was found to exist between exons 4 and 5 (originating
from intron 4, a cassette exon). To speciﬁcally examine this
region of the mRNA, we conducted PCR on all cases using a
forward primer designed against sequence in exon 4
(50-acatgagagctgccaacctt-30), and a reverse primer designed
against sequence in exon 5 (50-ggttcctgtccaagagcaag-30).
A3 0ml reaction mixture was assembled consisting of second
round cDNA diluted 1:1000, dNTP mix (0.2 mM in ﬁnal
concentration), forward and reverse primers (0.2 mMe a c hi n
ﬁnal concentration), Platinum Taq PCR buffer, 1.5 mM MgCl2
and 1.8 U of Platinum Taq DNA polymerase (Invitrogen life
technologies, Carlsbad, CA, USA). The cycle conditions were
948C for 30 s, 558C for 30 s and 728C for 1 min for 35 ampli-
ﬁcation cycles and the expected wild-type fragment size was
499 bp. PCR products were electrophoresed in 2% agarose
gels, and selected products were excised, gel puriﬁed using
the QIAquick Gel Extraction Kit (Qiagen Inc., Valencia,
CA, USA), and bi-directionally sequenced (Lofstrand Labs
Unlimited, Gaithersburg, MD, USA).
Generation of plasmid construct
pDsRed-wt-ESR1 and pDsRed-D7-ESR1 were constructed by
PCR ampliﬁcation of full-length human wild-type ESR1 or D7
ESR1 from commercially available MCF-7 cDNA (BioChain
Institute, Inc. Hayward, CA, USA). Primer pairs used in the
ampliﬁcation contained both XhoIa n dBamI restriction sites.
Primer sequences were: Forward 50-CTCGAGACCATGACCC
TCCAC-30 and Reverse 50-GGATCCTCAGACCGTGGCA
GGGA-30.E a c h2 5 ml reaction contained 0.5 ml cDNA tem-
plate, PCR buffer, 0.2 mM dNTPs, 2 mM MgCl2, and 0.02 U
of KOD Hot Start DNA polymerase (Merck KGaA, Darmstadt,
Germany). The cycling conditions were 958Cf o r2 m i n ,4 0
cycles of 958C for 40 s, 688Cf o r1m i n ,7 0 8Cf o r2 . 5m i na n d
708C for 3 min. PCR products were electrophoresed in 1%
agarose gels and products corresponding to the approximate
size of wild-type and D7E S R 1w e r ee x c i s e da n dg e l - p u r i ﬁ e d
using the QIAquick Gel Extraction Kit (Qiagen Inc., Valencia,
CA, USA). For the addition of 30-A overhangs, a 25 ml reaction
containing puriﬁed PCR product, PCR buffer, 0.2 mM dATP
(Promega Corporation), 2 mM MgCl2 and 0.5 U of Red Hotw
DNA polymerase (ABgene, Epsom, Surrey, UK) were incubated
at 728C for 30 min. Reaction products were then puriﬁed and
ligated into pcDNA3.1-V5-His using the TOPO TA cloning
kit (Invitrogen Australia Pty Limited, Victoria, Australia)
according to the manufacturer’s instructions. Positive clones
containing inserts for ESR1 wild-type and D7 were veriﬁed by
sequencing. Both genes were then excised by restriction endonu-
clease digestion with XhoIa n dBamI, gel puriﬁed and ligated
into pDsRed-express-C1 (Clontech Laboratories, Inc. Mountain
View, CA, USA) using T4 DNA ligase (Fermentas, Glen
Burnie, MD, USA) according to the manufacturer’s instructions.
Cell culture
CHOK-1 cells were grown at 378C in a 5% CO2 atmosphere
and cultured in Dulbecco’s modiﬁed Eagle’s medium/Ham’s
F-12 medium (1:1 mixture) containing 10% (v/v) heat- inacti-
vated fetal bovine serum supplemented with penicillin/
streptomycin 100 U/100 mg/ml and glutamax (2 mM)
(Invitrogen Australia Pty Limited, Victoria, Australia).
Luciferase reporter assay
On day 1, CHOK-1 cells were seeded into 48-well plates and
grown to 50% conﬂuence. On day 2, the growth media was
removed and cells were washed twice in phosphate buffered
saline. Cells were then refreshed with Dulbecco’s modiﬁed
Eagle’s medium/Ham’s F-12 medium (1:1 mixture) containing
10% (v/v) charcoal-stripped-heat-inactivated fetal bovine
serum supplemented with penicillin/streptomycin 100 U/
100 mg/ml and glutamax (2 mM) (Invitrogen Australia Pty
Limited, Victoria, Australia). On day 3, CHOK-1 cells were
transiently transfected for 24 h using Lipofectamine 2000
(Invitrogen Australia Pty Limited, Victoria, Australia)
(0.5 ml/well) in charcoal-stripped media containing no anti-
biotics. Plasmids transfected included the 3x ERE-luc reporter
plasmid (125 ng/well) (a kind gift from Professor Rakesh
Kumar, PhD (M.D. Anderson, Houston, TX, USA),
pDsRed-wt-ESR1 (12.5 ng/well) and/or pDsRed-D7-ESR1
(12.5 alone and 37.5 ng/well in combination with wt). The
empty vector pDsRed-express-C1 was used to total the DNA
content of the overexpression plasmids to 50 ng/well. The
phRL-TK Renilla internal control plasmid (12.5 ng/well) was
also co-transfected for normalization of transfection efﬁ-
ciency. On day 4, the transfection media was removed and
2306 Human Molecular Genetics, 2008, Vol. 17, No. 15cells were incubated with the absence and presence of 50 pM
of 17b-estradiol (Dr Ehrenstorfer GmbH, Augsburg,
Germany) for 24 h. On day 5, cells were washed and
resuspended in 50 mlo f1   passive lysis buffer (Promega
Corporation). Luciferase assays were performed using the
Dual Luciferase Assay Reporter System (Promega Corpor-
ation) according to the manufacturer’s instructions in a
FLUOstar OPTIMA plate reader (BMG Lab Tech, Offenburg,
Germany). The results were normalized and expressed as the
ratio of luciferase activity to the Renilla internal control, and
normalized to the vehicle-treated control condition.
Statistical analysis
Case–control association analysis. Schizophrenics and con-
trols from the postmortem brain collection were stratiﬁed by
race to test for genetic association between ESR1 and schizo-
phrenia within each racial group. Caucasians and African
Americans of both genders were included in this case–control
genetic analysis. Common SNPs (N ¼ 10, MAF.6%) of the
two case–control samples corresponding to 88 schizophrenics
(45 African Americans and 43 Caucasians) and 137 normal
controls (87 African Americans and 50 Caucasians) were
typed and used for pairwise and haplotype case–control associ-
ation analysis. Pairwise case–control allele and genotype
frequency comparison were performed with FINETTI version
July 2002 (http://www.mds.qmw.ac.uk/statgen/dcurtis/
software.html) and COCAPHASE of the UNPHASED
program version 3.0.2 (74). Marker-to-marker LD for both
Caucasians and African Americans was calculated using
HAPLOVIEW version 3.32 (75).
Family-based association analysis. In order to test for associ-
ation between ESR1 and schizophrenia in an independent
clinical sample, we performed a TDT in DNA from the
nuclear families available from the NIMHRGI. In these
nuclear families, we genotyped the same high frequency
SNPs which were genotyped by TaqMan and re-sequencing
in the postmortem brain sample. Mendelization errors and
improbable recombination were checked with MERLIN
0.10.2 and excluded from the analysis. We tested for allele
and haplotype transmission disequilibrium using TDTPHASE
of the UNPHASED program version 2.03. The allele and
haplotype analyses were performed in each population
(African Americans and Caucasians) separately and combined.
In using TDTPHASE, we assumed no linkage and excluded
missing data. We ran the pairwise analysis by including only
certain transmissions. The uncertain option was used to increase
the number of analyzed transmissions in the haplotype analysis.
Diagnosis and genotype analyses of prefrontal cortical ESR1
mRNA levels. ESR1 genotypic and diagnostic effects were
analyzed in relation to ESR1 mRNA expression via two-way
ANCOVAs. ESR1 mRNA levels decrease with age
(r ¼ 20.413, P ¼ 0.001); therefore, age was used as a covariant
in all statistical tests. PMI, pH, RIN and neuroleptic treatment
w e r en o tc o r r e l a t e dw i t hE S R 1m RNA quantities. ESR1 mRNA
levels were averaged from the triplicate measures and population
outliers that were two standard deviations above or below the
mean of the entire cohort were removed. ANCOVAs were
run in two different ways with respect to the genotype variable.
Genotype (11 versus 12 versus 22) was considered the indepen-
dent factor and if there was a very low sample size (n ¼ ,5) in
the homozygous rare allele group, the genotypes were combined
into carriers of the rare allele (12 and 22) versus non-carriers
of the rare allele (11) to increase the power. For all SNPs with a
signiﬁcant effect of diagnosis, genotype or an interaction effect,
post hoc Fisher’s LSD test was performed.
ESR1 mRNA variants frequency and SNP association analysis.
Observed expression frequencies of the wild-type and common
exon-deleted ESR1 mRNA variant were subjected to chi-square
statistical analysis to determine if frequencies of ESR1 mRNA
variant detection in patients diagnosed with major mental
illness differed from the frequency of detection observed in
normal controls (29). In addition, genotypes of SNPs with a
MAF .5% located within 200 bp either in the intron preceding
or following the ESR1 exons 5 (C25) and 7 (C32 and C33),
were used to examine the potential relationship between the
most common ESR1 mRNA deleted variants (D5a n dD7)
and the DNA variation present in putative splicing regions.
Luciferase reporter assay for ESR1 wild-type and D7.T h e
effect of transfection of control, wild-type and wild-type þD7
ESR1 plasmids on ERE-driven luciferase reporter activity at
two different dosages was assessed by two-way ANOVA (treat-
ment condition and estrogen levels as IV) and subject to
post-hoc Fisher’s LSD analysis (n ¼ 6 wells in each condition).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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